Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London
Highlights at the International Trade Commission in 2016 included the most Section 337 investigations since 2011, the first live hearing for a decade and the first antitrust claim for 25 years. Michael Loney asks ITC practitioners what trends they expect in 2017
While 2016 was a quiet year for design decisions in the Court of Justice, 2017 looks to be a cracker year of important cases. In the first of two articles, David Stone looks back at the year that was. Next month, he looks forward to some of the key decisions expected in 2017
Christopher M Neumeyer reviews the lessons to be learned from two recent cases where Taiwan companies were ordered to pay taxes on licensing fees paid to a foreign licensor
Nick McDonald looks at the characteristics of an effective IP strategy and the dangers of failing to keep it alive in a business
In this, the second part of this year’s IP Stars research, we rank the top firms in 80 jurisdictions for patent work
Africa is highly attractive to counterfeiters. But, explains Chris Walters, several governments in the continent have recently taken action to tackle the problem
3D printing is already causing disruption in some industries. Stella Wong considers how to develop a 3DP IP strategy, with a particular focus on the medical industry
Inspired by Valentine’s Day last month, Managing IP invited our Twitter followers to compose IP-related love poems, and received dozens of responses, from the beautiful to the bitter. Utynam has picked his favourites to share with you
Federal Circuit’s Brunetti ruling: barring immoral or scandalous marks is unconstitutional restriction of free spee… https://t.co/MivCKFINHg
Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS https://t.co/uYIkfVhCHG https://t.co/2OZAscsz32
RT @mdloney: Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations https://t.co…
End of Year 2017
Tribal sovereign immunity: Taking a wrecking ball to the IPR system
The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International